BMEA vs. EOLS, BNTC, YMAB, KMDA, TVRD, IMAB, DSGN, IVVD, AMRN, and UPXI
Should you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Evolus (EOLS), Benitec Biopharma (BNTC), Y-mAbs Therapeutics (YMAB), Kamada (KMDA), Tvardi Therapeutics (TVRD), I-Mab (IMAB), Design Therapeutics (DSGN), Invivyd (IVVD), Amarin (AMRN), and Upexi (UPXI). These companies are all part of the "pharmaceutical products" industry.
Biomea Fusion vs. Its Competitors
Biomea Fusion (NASDAQ:BMEA) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.
96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 18.4% of Biomea Fusion shares are owned by company insiders. Comparatively, 5.9% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Biomea Fusion presently has a consensus target price of $9.50, suggesting a potential upside of 588.41%. Evolus has a consensus target price of $21.25, suggesting a potential upside of 214.81%. Given Biomea Fusion's stronger consensus rating and higher probable upside, equities analysts plainly believe Biomea Fusion is more favorable than Evolus.
In the previous week, Biomea Fusion had 1 more articles in the media than Evolus. MarketBeat recorded 2 mentions for Biomea Fusion and 1 mentions for Evolus. Biomea Fusion's average media sentiment score of 0.82 beat Evolus' score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the media.
Biomea Fusion has a net margin of 0.00% compared to Evolus' net margin of -22.31%. Biomea Fusion's return on equity of -243.95% beat Evolus' return on equity.
Evolus has higher revenue and earnings than Biomea Fusion. Evolus is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.
Biomea Fusion has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.
Summary
Biomea Fusion beats Evolus on 11 of the 16 factors compared between the two stocks.
Get Biomea Fusion News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biomea Fusion Competitors List
Related Companies and Tools
This page (NASDAQ:BMEA) was last updated on 10/24/2025 by MarketBeat.com Staff
Free BMEA Stock Alerts